BioAtla

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

michael burry

Equities

News

Markets

ACIC

AMZN

BABA

BCAB

BIDU

FOUR

GOOG

GOOGL

OLPX

REAL

Michael Burry, the investor renowned for his prescient bet against the housing market before the 2008 financial crisis, has seen his recent wager on Chinese stocks pay significant dividends. 

&#39;Big Short&#39; Investor Michael Burry&#39;s China Bet Pays Off As Top Picks Surge Nearly 60% In 2 Months

Michael Burry illustration by Gonzalo Lanzilotta for Benzinga

Asia

Global

Famed investor Michael Burry, known for his prescient bet against the housing market before the 2008 financial crisis, has made significant changes to his hedge fund&#39;s portfolio in the second quarter of 2024. 

&#39;Big Short&#39; Fame Michael Burry Bets Big On China, Reveals Alibaba As Top Holding — JD.com And Baidu Also Feature On Scion&#39;s Portfolio

Long Ideas

Penny Stocks

Insider Trades

Pre-Market Outlook

Trading Ideas

CRDF

CYAN

XAIR

The Dow Jones index closed higher by around 250 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Around $2M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

BioAtla Inc

Health Care

Press Releases

BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024

Earnings

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Financing

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

CNTX

ABVC BioPharma

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

BioVie

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

CervoMed

GlycoMimetics

HCW Biologics

HOOKIPA Pharma

IN8bio

Kairos Pharma

Longeveron

Leap Therapeutics

Lisata Therapeutics

MEI Pharma

Marker Therapeutics

NKGen Biotech

Nanoviricides

NextCure

Palatin Techs

Spruce Biosciences

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings)

Tenax Therapeutics

JMP Securities

JP Morgan

EF Hutton

BTIG

Credit Suisse

Comments

BioAtla

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga